MMED008
105 evidence topics · 15 sources
Objective
Objective stated in the publication
“To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current phase 2b study assessed the dose response, efficacy, safety, and tolerability of a single treatment with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 vs placebo in participants with moderate to severe GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary, key secondary, and exploratory objectives in the protocol
Sponsor statement of the primary and key secondary objectives
Location and study date
Study dates in the registry
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2022-08-24” |
| Primary completion (actual) | “2023-10-06” |
| Study completion (actual) | “2023-11-27” |
| First posted | “2022-06-07” |
| Results first posted | “2025-03-20” |
Registered locations
Sites and conduct period reported in the publication
“was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The last date of follow-up was November 27, 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was conducted at 22 outpatient psychiatric research sites across the US (eTable 2 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of clinical sites at completion of enrollment, September 2023, superseded in September 2025
Topline Week 12 results, March 2024
Journal publication, September 2025
Study design
Phase 2b randomized, double-blind, placebo-controlled, five-arm dose-finding design
“In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included 3 phases: (1) eligibility assessment (up to 35 days), (2) randomization (1 day), and (3) follow-up (12 weeks) (eFigure 1 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Protocol design and allocation ratio
Registry design fields
| Field | Registry record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Other study ID | “MMED008” |
Rationale for the dose levels and the placebo control
Blinded central rating of efficacy outcomes
“The HAM-A and the Montgomery-Åsberg Depression Rating Scale (MADRS) scores were assessed by independent central raters via telephone; the raters were blinded to the trial protocol, treatment allocation, and study visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To mitigate bias, the dosing session monitors were prohibited from conducting the efficacy assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single administration with no psychotherapeutic intervention
Eligibility criteria
Key eligibility criteria reported in the publication
“The eligibility criteria included age of 18 to 74 years, having a Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) primary diagnosis of GAD based on investigator assessment and confirmed by a Mini-International Neuropsychiatric Interview, and having moderate to severe anxiety (Hamilton Anxiety Rating Scale [HAM-A] score of ≥20) at both screening and at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria in the protocol
Key exclusion criteria in the protocol: psychiatric history and substance use
Key exclusion criteria in the protocol: cardiovascular conditions
Suicide risk exclusion in the registry
Concurrent psychotherapy
“Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study. Participants not receiving psychotherapy at screening could not initiate it during the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Treatment arms in the registry
| Arm | Registry record |
|---|---|
| Placebo | “Placebo Comparator: Arm 1- Placebo” |
| Lysergide 25 µg | “Experimental: Arm 2- 25 μg MM120” |
| Lysergide 50 µg | “Experimental: Arm 3- 50 μg MM120” |
| Lysergide 100 µg | “Experimental: Arm 4- 100 μg MM120” |
| Lysergide 200 µg | “Experimental: Arm 5- 200 μg MM120” |
| Intervention description | “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).” |
Number randomized to each arm
Capsule formulation and blinded dose preparation
Medication taper and washout before dosing
“Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians. Before the baseline visit, a medication washout period of 5 half-lives or greater was required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dosing session procedures and monitoring
“On the dosing day, participants received a single oral dose of MM120 or placebo. Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participant dosing sessions were conducted individually in a private aesthetically pleasant room. The dosing sessions were not recorded or conducted in a group setting. Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1). Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects. Continuous monitoring was required for a minimum of 12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dosing session monitor qualifications
Study outcomes
Rationale for using hamilton anxiety rating scale Dose-Response at week 4 as the primary endpoint
Primary endpoint definition
“The primary outcome was a dose-response relationship assessed using the multiple comparison procedure modeling (MCP-Mod) method for change in HAM-A score at 4 weeks (score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The HAM-A score was assessed by independent central raters using the Structured Interview Guide for the Hamilton Anxiety Rating Scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered primary outcome and HAM-A items
Protocol rationale for the HAM-A as the efficacy measure
Protocol rationale for the Week 4 time point, the Week 8 key secondary endpoint, and the HAM-A entry threshold
Rationale for the MCP-Mod analysis and the minimal clinically important difference
“The primary outcome and the key secondary outcome were evaluated using the MCP-Mod approach at the 5% significance level, which integrates hypothesis testing with dose-response modeling and is endorsed by regulatory agencies for dose selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A placebo-adjusted difference of 2.5 points for change in HAM-A score was used as the threshold (minimal clinically important difference of 2.5 points) for determining the minimally efficacious dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary, secondary, and exploratory endpoints
“The key secondary outcome was a dose-response relationship” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“assessed using the MCP-Mod method for change in HAM-A score at 8 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of response (≥50% change [reduction] in HAM-A score from baseline) and remission (HAM-A score ≤7) were also explored.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of MM120 on functional disability, quality of life, and sexual function were assessed throughout the trial using the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blinding of the participants and raters regarding treatment allocation (active drug, placebo, or indiscernible) was assessed using a 5-point questionnaire (range, 1 [positive they received drug] to 5 [positive they received placebo]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety endpoints
“Safety and tolerability were evaluated through adverse event (AE) monitoring, physical and neuropsychiatric examinations, vital signs, electrocardiographic monitoring, and laboratory tests. Suicidal ideation and behavior were assessed at each visit using the Columbia–Suicide Severity Rating Scale (C-SSRS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Target sample size in protocol version 6.0, July 2023
Planned enrollment at first participant dosing, August 2022
Participants randomized and analyzed
Description of analysis sets
Analysis sets used for efficacy and safety
“Efficacy was analyzed in the full analysis set, which was composed of all randomized participants with a HAM-A measurement at baseline and at least 1 HAM-A measurement after baseline. Safety was evaluated in all participants who were randomized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets defined in the statistical analysis plan
MCP-Mod testing procedure and dose-response models
“Six candidate dose-response models were prespecified to represent a range of plausible dose-response shapes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“assessed under strict type I error control at the 5% level using a hierarchical gatekeeping testing procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated dose-response curve was derived using an Akaike information criterion–weighted average of the top 3 dose-response models.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of missing data and intercurrent events
“Missing primary end point data were imputed using multiple imputations with 20 iterations. Observations missing due to prohibited medication use were assumed to be missing not at random and imputed using placebo-based imputation. All other missing observations were imputed under the assumption of missing at random.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary analyses without imputation or multiplicity adjustment
“Change in HAM-A score from baseline was analyzed using an analysis of covariance model adjusted for the baseline values and treatment group without imputation (observed cases only).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other secondary efficacy outcomes were analyzed using 2-sample t tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect size calculation
“Cohen d was calculated as the bias-corrected least-squares estimate of the treatment difference in changes from baseline to a given time point (from an analysis of covariance model), divided by the pooled SD of observed values at the same time point from a given active dose group and the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrollment period and randomization in the publication
“Between August 24, 2022, and August 30, 2023, a total of 554 participants were screened; of these, 198 were randomized and received a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Completion through Week 4 in the topline announcement
Baseline characteristics
Demographics of the full analysis set
“Of the 198 participants randomized, 194 were included in the full analysis set (mean age, 41.3 [SD, 13.6] years; 56.7% were female; and 3.6% were Asian, 7.7% were Black or African American, and 83.0% were White) (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean HAM-A scores at baseline were equivalent across groups (score range, 29.3-31.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline demographics and disease characteristics by arm
Prior treatment and medication taper at screening
“At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial. Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline severity described by the sponsor
Efficacy results
Primary endpoint: MCP-Mod dose-response for HAM-A change at Week 4
“A significant MM120 dose-response relationship was demonstrated at both week 4 (primary outcome) and week 8 (key secondary outcome) based on changes from baseline in HAM-A score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 4, the adjusted critical value was 2.032 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 3.294, 3.149, 3.133, 1.448, 3.471, and 2.971, respectively. Therefore, 5 of the 6 models, including the linear, Emax, and multiple sigmoid Emax variants, met the significance threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the primary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −5.0 points [95% CI, −9.6 to −0.4 points] with 100 µg of MM120 and −6.0 points [95% CI, −9.8 to −2.0 points] with 200 µg of MM120) but the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −1.2 points [95% CI, −6.0 to 3.5 points] with 25 µg of MM120 and −1.8 points [95% CI, −7.6 to 4.0 points] with 50 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint: model-based estimates at Week 4 by arm
| Arm | Least-squares mean change (95% CI) | Least-squares mean difference vs placebo (95% CI) |
|---|---|---|
| Placebo | “−14.2 (−17.8 to −10.6)”View highlighted excerpt for this quote | Not applicable |
| Lysergide 25 µg | “−15.4 (−17.6 to −13.1)”View highlighted excerpt for this quote | “−1.2 (−6.0 to 3.5)”View highlighted excerpt for this quote |
| Lysergide 50 µg | “−16.0 (−19.4 to −12.7)”View highlighted excerpt for this quote | “−1.8 (−7.6 to 4.0)”View highlighted excerpt for this quote |
| Lysergide 100 µg | “−19.2 (−21.7 to −16.7)”View highlighted excerpt for this quote | “−5.0 (−9.6 to −0.4)”View highlighted excerpt for this quote |
| Lysergide 200 µg | “−20.1 (−22.9 to −17.3)”View highlighted excerpt for this quote | “−6.0 (−9.8 to −2.0)”View highlighted excerpt for this quote |
Primary endpoint as posted on the registry
| Arm | Mean change from baseline to Week 4, model averaging (95% CI) | Mean difference from placebo (95% CI) |
|---|---|---|
| Placebo | “-14.23 (-17.83 to -10.63)” | Not applicable |
| Lysergide 25 µg | “-15.35 (-17.62 to -13.09)” | “-1.24 (-6.01 to 3.53)” |
| Lysergide 50 µg | “-16.05 (-19.40 to -12.71)” | “-1.82 (-7.65 to 4.00)” |
| Lysergide 100 µg | “-19.22 (-21.73 to -16.70)” | “-5.02 (-9.60 to -0.44)” |
| Lysergide 200 µg | “-20.09 (-22.87 to -17.31)” | “-5.95 (-9.84 to -2.06)” |
Minimally efficacious dose
“These selected models at each time point were incorporated into an Akaike information criterion–weighted model-averaging procedure to estimate the dose-response curve and calculate the minimally efficacious dose, which was found to be between 56.7 µg and 85.1 µg (eFigure 2 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: MCP-Mod dose-response for HAM-A change at Week 8
“At week 8, the adjusted critical value was 2.041 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 2.099, 2.922, 2.938, 2.254, 2.690, and 2.778, respectively. Therefore, all 6 models met the significance threshold, with the linear, Emax, and sigmoid Emax models selected as the best fitting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the key secondary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 8 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −2.9 points [95% CI, −5.4 to −0.5 points] with 100 µg of MM120 and −5.4 points [95% CI, −9.5 to −1.4 points] with 200 µg of MM120) but” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −0.8 points [95% CI, −1.7 to 0.2 points] with 25 µg of MM120 and −1.4 points [95% CI, −3.1 to 0.2 points] with 50 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 4 HAM-A difference at 100 µg: observed-case ANCOVA secondary analysis in the publication
“For the secondary outcome at week 4, the 100-µg and the 200-µg dose groups significantly reduced HAM-A score vs placebo (the least-squares mean difference was −7.6 points [95% CI, −11.8 to −3.4 points; P < .001; Cohen d = 0.88] with 100 µg of MM120 and was −5.5 points [95% CI, −9.7 to −1.3 points; P = .01; Cohen d = 0.64] with 200 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 4, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −3.4 points (95% CI, −7.7 to 0.9 points; P = .12) with 25 µg of MM120 and the reduction was −0.9 points (95% CI, −5.2 to 3.3 points; P = .66) with 50 µg of MM120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 4 HAM-A difference at 100 µg: company topline announcement, December 2023
Week 4 HAM-A difference at 100 µg: company publication announcement, September 2025
HAM-A change from baseline by week: observed-case ANCOVA differences from placebo
HAM-A change at Weeks 8 and 12
“For the secondary outcome at week 8, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −4.3 points (95% CI, −8.9 to 0.3 points; P = .06; Cohen d = 0.48) for 100 µg of MM120 and the reduction was −5.5 points (95% CI, −10.2 to −0.8 points; P = .02; Cohen d = 0.60) for 200 µg of MM120. At week 12, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −7.7 points (95% CI, −12.6 to −2.8 points; P = .003; Cohen d = 0.81) with 100 µg of MM120 and the reduction was −7.4 points (95% CI, −12.4 to −2.4 points; P = .004; Cohen d = 0.77) with 200 µg of MM120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A change at Week 12: company topline announcement, March 2024
HAM-A response and remission at Week 12
“The secondary outcome of HAM-A response (defined by a 50% reduction in total score) at week 12 was achieved by 65.0% of participants in the 100-µg dose group and by 62.5% in the 200-µg dose group compared with 30.8% of participants in the placebo group and the remission rates at week 12 were 47.5%, 45.0%, and 20.5%, respectively (eFigure 4 and eTable 3 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A response and remission at Weeks 4 and 12 by arm
| Outcome | Placebo (n=39) | 25 μg (n=39) | 50 μg (n=36) | 100 μg (n=40) | 200 μg (n=40) |
|---|---|---|---|---|---|
| Response, Week 4, n (%) | “12 (30.8%)” | “20 (51.3%)” | “21 (58.3%)” | “31 (77.5%)” | “31 (77.5%)” |
| Response, Week 12, n (%) | “12 (30.8%)” | “17 (43.6%)” | “20 (55.6%)” | “26 (65.0%)” | “25 (62.5%)” |
| Remission, Week 4, n (%) | “7 (17.9%)” | “11 (28.2%)” | “9 (25.0%)” | “20 (50.0%)” | “14 (35.0%)” |
| Remission, Week 12, n (%) | “8 (20.5%)” | “11 (28.2%)” | “12 (33.3%)” | “19 (47.5%)” | “18 (45.0%)” |
HAM-A response and remission at Week 4: company topline announcement, December 2023
Clinician-rated illness severity (CGI-S)
“The statistically significant improvements in illness severity (measured using the CGI-S score) were observed on day 2 and at weeks 2 through 12 in the 100-µg and 200-µg dose groups, but not in the 25-µg or 50-µg dose groups or in the placebo group. At week 1, all MM120 dose groups demonstrated significant improvements, but the placebo group did not” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CGI-S mean difference from placebo on Day 2 and at Week 12
CGI-S change described by the sponsor
Depressive symptoms (MADRS)
MADRS mean difference from placebo at Weeks 4 and 12
MADRS change described by the sponsor
Functional unblinding and placebo response
“All doses of MM120 produced transient perceptual, cognitive, and emotional effects leading to participant unblinding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“despite approximately 85% of participants correctly identifying assignment to active treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, even though more than 65% of participants accurately identified their assignment as placebo recipients, a robust placebo effect was observed that was comparable with or exceeded trials of anxiolytics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup analyses
Health-related quality of life and patient-reported outcomes
Functional, quality-of-life, sleep, and sexual function outcomes reported in the supplement
“Additional secondary outcomes, including changes in scores for the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire appear in eTable 6 in Supplement 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the secondary outcomes focused on functional disability, the changes from baseline were analyzed descriptively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sheehan Disability Scale total score at Week 12
| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
|---|---|---|---|
| Placebo | “-8.2 (8.61)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-10.8 (7.72)” | “-2.59” | “(-7.10 to 1.91)” |
| Lysergide 50 μg | “-9.0 (9.17)” | “-0.83” | “(-5.70 to 4.03)” |
| Lysergide 100 μg | “-15.1 (5.78)” | “-6.86” | “(-10.89 to -2.83)” |
| Lysergide 200 μg | “-13.1 (7.51)” | “-4.93” | “(-9.33 to -0.53)” |
EQ-5D-5L visual analog scale at Week 12
| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
|---|---|---|---|
| Placebo | “11.7 (18.24)” | Not applicable | Not applicable |
| Lysergide 25 μg | “17.0 (18.53)” | “5.31” | “(-4.65 to 15.27)” |
| Lysergide 50 μg | “13.2 (13.97)” | “1.55” | “(-7.34 to 10.45)” |
| Lysergide 100 μg | “17.7 (13.68)” | “6.04” | “(-2.61 to 14.70)” |
| Lysergide 200 μg | “17.3 (19.40)” | “5.64” | “(-4.37 to 15.65)” |
Pittsburgh Sleep Quality Index global score at Week 12
| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
|---|---|---|---|
| Placebo | “-4.3 (4.22)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-5.5 (4.01)” | “-1.25” | “(-3.48 to 0.99)” |
| Lysergide 50 μg | “-4.8 (3.88)” | “-0.55” | “(-2.77 to 1.67)” |
| Lysergide 100 μg | “-5.9 (4.13)” | “-1.64” | “(-3.84 to 0.56)” |
| Lysergide 200 μg | “-4.9 (4.11)” | “-0.60” | “(-2.83 to 1.62)” |
Patient Global Impression of Severity and of Change at Week 12
| Arm | PGI-S difference from placebo in mean change | PGI-S 95% CI | PGI-C observed mean (SD) | PGI-C difference from placebo | PGI-C 95% CI |
|---|---|---|---|---|---|
| Placebo | Not applicable | Not applicable | “2.2 (0.98)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-0.34” | “(-0.91 to 0.24)” | “1.8 (0.71)” | “-0.36” | “(-0.83 to 0.10)” |
| Lysergide 50 μg | “-0.30” | “(-0.94 to 0.34)” | “1.8 (1.00)” | “-0.36” | “(-0.90 to 0.17)” |
| Lysergide 100 μg | “-0.47” | “(-1.05 to 0.11)” | “1.5 (0.67)” | “-0.71” | “(-1.16 to -0.25)” |
| Lysergide 200 μg | “-0.37” | “(-1.01 to 0.26)” | “1.7 (0.98)” | “-0.51” | “(-1.04 to 0.01)” |
Sexual dysfunction (ASEX) at Week 12
| Arm | Females with sexual dysfunction, n (%) | Males with sexual dysfunction, n (%) |
|---|---|---|
| Placebo | “6 (33.3)” | “1 (12.5)” |
| Lysergide 25 μg | “4 (25.0)” | “3 (23.1)” |
| Lysergide 50 μg | “10 (66.7)” | “1 (7.1)” |
| Lysergide 100 μg | “6 (46.2)” | “2 (10.0)” |
| Lysergide 200 μg | “7 (33.3)” | “0 (0)” |
Safety results
Overview of adverse events
“The rate for 1 or more treatment-emergent adverse events (TEAEs) was 76.9% in the 25 µg of MM120 group, was 90.0% in the 50-µg group, was 97.5% in the 100-µg group, and was 100% in the 200-µg group vs 56.4% in the placebo group (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of all the AEs, 98.5% occurred on the dosing day and most resolved by the end of the dosing session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in the safety population by arm
Most frequent dosing-day adverse events at 100 µg and 200 µg
“On the dosing days, the most frequent AEs reported in the 100-µg and 200-µg dose groups were visual perceptual changes (illusion, pseudo-hallucination, hallucination) in 92.5% and 100% of participants, respectively, nausea in 40.0% and 60.0%, headache in 35.0% and 27.5%, and euphoric mood in 27.5% and 15.0%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Most common adverse events as stated in the company publication announcement, September 2025
Serious adverse events
Suicidal ideation and behavior
“No participants engaged in self-injurious or suicidal behavior, which was assessed using the C-SSRS and AE reporting. There were no reports of suicidal ideation with intent or a plan during the sessions or throughout the trial. Participants with a history of suicidal ideation showed no increase in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal ideation reported as an adverse event in the registry
| Arm | Affected / at risk (%) |
|---|---|
| Placebo | “1/39 (2.56%)” |
| Lysergide 25 μg | “1/39 (2.56%)” |
| Lysergide 50 μg | “2/40 (5.00%)” |
| Lysergide 100 μg | “2/40 (5.00%)” |
| Lysergide 200 μg | “0/40 (0.00%)” |
Resolution of acute effects and time to meeting session-end criteria
“Resolution of acute effects from MM120 was observed in more than 97% of participants at all MM120 doses by 12 hours after the dose was administered (eFigure 6 in Supplement 3). In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours. All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor summary of tolerability
Pooled safety analysis including the phase 2b 100 µg and 200 µg arms
Study limitations
Summary
The trial randomized 198 participants at 22 outpatient sites in the United States to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, with 12 weeks of follow-up and no study-related psychotherapy. The phase 3 trials use an orally disintegrating tablet, so the phase 2b results were obtained with a different formulation.
- Primary analysis and reported effect size: the prespecified MCP-Mod primary analysis with multiple imputation gave a least-squares mean difference from placebo at Week 4 of −5.0 points (95% CI, −9.6 to −0.4) for 100 µg. The 7.6-point difference (Cohen d = 0.88) that company announcements report for Week 4 is the publication's secondary outcome at Week 4. The publication states that change in HAM-A score from baseline was analyzed by analysis of covariance without imputation (observed cases only), while missing primary end point data were imputed by multiple imputation; the registry results state that missing data were not imputed for non-key secondary efficacy endpoints.
- Multiplicity: only the primary and key secondary outcomes were controlled for type I error; other hypothesis tests, including the Week 12 difference of −7.7 points and the response and remission rates, were not adjusted for multiple comparisons.
- Functional unblinding: the authors state that the perceptible drug effects may have led to unblinding, and approximately 85% of participants correctly identified assignment to active treatment. Efficacy was rated by central raters blinded to protocol, treatment allocation, and visit.
- Dosing session monitors: two monitors were present throughout each session, and the authors state that confounding effects of interpersonal interactions remain a possibility.
- Missing data: 147 of 198 randomized participants (74.2%) completed the study, and the authors describe the dropout rate as slightly higher than in studies of similar molecules.
- Population: participants were physically healthy with limited psychiatric comorbidities, discontinued anxiolytic and antidepressant medications before dosing, and 83.0% were White; 18% received psychotherapy outside the trial.
- Sample size: 36 to 40 participants per arm in the full analysis set; analyses by sex and other characteristics were not conducted because of insufficient statistical power.
- Adverse event figures for visual perceptual changes, nausea, and headache in the company publication announcement differ from those in the journal article (for example, nausea at 100 µg 42.5% versus 40.0%).
Limitations stated in the publication
“Despite dosing session monitors explicitly not providing a systematic psychotherapeutic intervention, confounding effects of interpersonal interactions remain a possibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, the perceptible drug effects of MM120 may have led to unblinding, which could have influenced the outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, the primary outcome and key secondary outcome were strictly controlled for type I error, but the other hypothesis tests were not adjusted for multiple comparisons. Fourth, the dropout rate, though similar across groups, was slightly higher than in studies of similar molecules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This higher dropout rate may be due to the 12-week duration of the trial, the required discontinuation of GAD medications, and the absence of an extension phase with opportunities for open-label treatment. Fifth, the participants were physically healthy with limited psychiatric comorbidities, potentially enhancing the tolerability of transient AEs. Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies. Seventh, some participants engaged in psychotherapy outside the trial, which may have affected dosing-day experiences and efficacy outcomes, though this was the case for only 18% of participants. Eighth, the study population was inclusive in terms of sex and age but was racially and ethnically less diverse than the general population of people with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote